Immunotherapy

Papers
(The H4-Index of Immunotherapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’69
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar63
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study51
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma40
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study40
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma35
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia31
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward29
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma29
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis27
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data26
Immunotherapy for Gastric Cancer: A 2021 Update24
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15823
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey21
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review20
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression19
Postvaccination immune-mediated hepatitis: what do we really know?18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas18
0.026780843734741